47 results about "Treatment study" patented technology

The invention relates to an integrated system and method for collecting information for the pharmaceutical industry to assess opinions concerning sales and marketing forces, prescribing patterns and attitudinal physician perceptions regarding specific pharmaceutical brands. These three areas are evaluated through three modules, each consisting of a separate survey administered via the internet, and capable of producing reports integrating all three areas. The surveys are entitled: 1) Continuous Promotion Tracking Study (CPT); 2) Rx Intentions and Treatment Study (RxIT); and 3) Therapeutic Class Attitude and Perception Study (TCAP).

The invention discloses a waist and abdomen (abdomen and waist) rehabilitation treatment machine. The waist and abdomen (abdomen and waist) rehabilitation treatment machine comprises a rack, wherein a hip and lower limb bracket for the part below the human sacroiliac joint and a head, chest and abdomen bracket for the part above the human pelvis are arranged on the rack along the longitudinal direction, and the waist and abdomen (abdomen and waist) rehabilitation treatment machine also comprises a human back work bracket which is arranged on the rack and positioned above the head, chest and abdomen bracket. The waist and abdomen (abdomen and waist) rehabilitation treatment machine has the advantages that on the basis of the clinical diagnosis and treatment practice of the department of orthopaedics of the traditional Chinese medicine and the western medicine, and through the observation and diagnosis and treatment study on the waist and abdomen (abdomen and waist) syndrome, the movements needed by functional recovery of the waist and abdomen (abdomen and waist) syndrome, namely, the application means needed by the all-side physiological function recovery, such as the massage to the abdomen, the dorsal stretch and traction to the body, the pull-press, push-movement, push pressing, lateral pull and lateral rotation for the waist, the traction shaking of the ankle, the body muscle loosing and the unique elastic impact and buffer massage for the waist and the back are scientifically applied to the functional rehabilitation treatment of the waist and the abdomen (abdomen and waist) through the mechanical working manner, and thus an effective rehabilitation treatment device is provided for the non-surgical treatment for the waist and abdomen (abdomen and waist) diseases.

The invention relates to an integrated system and method for collecting information for the pharmaceutical industry to assess opinions concerning sales and marketing forces, prescribing patterns and attitudinal physician perceptions regarding specific pharmaceutical brands. These three areas are evaluated through three modules, each consisting of a separate survey administered via the internet, and capable of producing reports integrating all three areas. The surveys are entitled: 1) Continuous Promotion Tracking Study (CPT); 2) Rx Intentions and Treatment Study (RxIT); and 3) Therapeutic Class Attitude and Perception Study (TCAP).

The invention discloses an artificial in-vitro preparation method of low molecular weight amyloid peptide oligomer and application, which is characterized in that the monomer of A beta polypeptide obtained with a gene recombination method is placed in a buffer system to react after dissolved by anhydrous dimethyl sulfoxide, thus naturally polymerizing to obtain oligomer. The method which obtains the monomer by gene recombination is economic and environmentally-friendly; when A beta serves as raw material to assemble amyloid peptide oligomer in vitro, a stable and even product is obtained by simulating in vivo physiological conditions and improving artificial cerebrospinal fluid components. The oligomer prepared with the method can serve as the standard reference for the detection and the therapy researches of various Alzheimer diseases, and can be applied in the diagnostic reagent and the therapy drug of the Alzheimer disease.

The invention belongs to the field of medicine and relates to a profile model for simulating the performance of the tumor contrast-enhanced ultrasonography and applied in the tumor diagnosis and treatment study. The profile model is characterized by comprising a tumor gel used for simulating a tumor, and a normal tissue gel used for simulating the surrounding normal tissue. The tumor gel comprises a nano micro-bubble ultrasonic contrast agent. The nano micro-bubble ultrasonic contrast agent is distributed uniformly, good in dispersibility, strong in imaging effect in vivo and in vitro, and better in stability in the high/low-frequency ultrasonic sound field. Therefore, the profile model facilitates the contrast-enhanced ultrasonic scanning process of a user, the practice of the tumor aspiration biopsy and the practice of the tumor ablation therapy with the help of the high/low-frequency ultrasonic guidance.

The invention belongs to the field of a medicinal preparation, and relates to an EGFR (epidermal growth factor receptor) modified platinum drug albumin nano preparation with a target tumor cell identification function. According to the invention, albumin is used for supporting platinum drugs, medical PEG (polyethylene glycol) is taken as a dispersing and cross-linking agent, and amination EGFR aptamer is taken as a target modifying molecule, so that the soluble albumin nano (Apt-PtNPs) preparation is prepared. The nanoparticle can be specifically combined with the EGFR on the surface of the tumor cell and has a cell endocytosis function, so that the toxic and side effects of the platinum drugs can be reduced, the purposes of toxicity reduction and efficacy enhancement are achieved, EGFR expression can be inhibited by prompting EGFR protein phosphorylation, and the anti-tumor effect of the nanoparticle in combination of the platinum drugs is achieved; the nanoparticle can be used for preparing the anti-tumor drugs, and particularly, the treatment research of the nanoparticle in the aspects of cervical cancer and ovarian cancer proves that the nanoparticle is good in targeting and good in killing effect and has good application prospect in gene therapy of tumors and combined treatment by chemotherapeutic drugs.

The invention belongs to the technical field of biomedicine, and in particular provides tumor vascular targeting peptide GX1. The invention utilizes a radioactive nuclide <99>Tc<m>O4 <-> to successfully mark GX1 by a direct method. Quality identification proves that <99>Tc<m>-GX1 has good radiochemical purity, specific activity and in vivo/vitro stability. In vitro microcosmic receptor autoradiography shows that the <99>Tc<m>-GX1 can combine with human umbilical vein endothelial cells and has good biological activity. In vitro microcosmic autoradiography, receptor radioligand conjoint analysis and competitive inhibition analysis confirm that the combination of the <99>Tc<m>-GX1 and tumor vascular endothelial cells has good specificity and affinity. ECT imaging and biological distribution prove that the <99>Tc<m>-GX1 has good targeting property to in vivo tumor tissue and specific distribution characteristicto tumor tissue. The <99>Tc<m>-GX1 has certain theoretical significance and great potential application value in diagnosis of gastric cancer, study on vascular targeting therapy, and other aspects.

The invention discloses an anti-tumor immunogene therapeutic medicament capable of activating the immunoreaction of the organism and having anti-tumor effect. The active ingredient of the anti-tumor immunogene therapeutic medicament is pVAX-IL-12-GB; three immunoregulation factor genes of human IL-12, GM-CSF and B7.1 are cloned to the same plasmid DNA vector pVAX1, and co-expression of upstream and downstream genes is realized through an internal ribosome entry site (IRES); and the vector is imported into a host so that the human immunoregulation factors IL-12, GM-CSF and B7.1 can be expressed simultaneously. The invention provides a novel anti-tumor immunogene therapeutic agent, wherein a plurality of anti-tumor immunoregulation factors are combined for use so that mutual costimulation of the factors can be developed and the organism can be better induced to produce anti-tumor immunoreaction; and therefore, the anti-tumor immunogene therapeutic medicament lays a firm foundation for further developing tumor immunogene treatment study and is wide in application prospect.

The invention discloses a cell telescoping structure model induced through mitosis retarding and a preparation method thereof. The method includes: retarding the mitosis metaphase through chemical drug or a genetics method to obtain a CIC cell model. The CIC cell model is induced through targeted retarding of mitosis. Building of the cell model is not limited in treatment mode and can be realizedno matter through the chemical drug or through the genetics method, and a stable and reliable model is provided for studying formation mechanism and physiological and pathological significance of CIC.Mitosis retarding induced CIC structure can be realized in normal epithelial cells, and the CIC cell model can be built in tumor cells. The CIC cell model can be built by using tumor targeting drug for targeted retarding of the mitosis metaphase, it shows that the model can serve as an in-vitro model for tumor therapy research.

The invention discloses application of a eukaryotic peptide chain release factor 3b fragment 36 (eRF3b-36) in the treatment of liver injury. The invention discloses application of the eRF3b-36 in the preparation of products for preventing and/or treating liver injury. According to the application, the eRF3b-36 has a good prevention and treatment effect on Con A induced acute hepatitis; in addition, shown by treatment research on fatty liver, dosed groups of the eRF3b-36 exert a good protecting effect on the liver regardless of whether in a serological index or hepatic histopathology, the level of ALT, AST, CHOL, TG and TBIL in blood serum can be remarkably lowered, and the content of free fat in liver tissue can be lowered; thus, a new possible direction and specific measures are provided for clinical liver disease treatment.

The invention discloses a single chain antibody and application thereof in inhibiting human tumor cells with highly expressed p21ras proteins. A gene segment of the single chain antibody is constructed by linking light and heavy chain variable region gene segments of p21ras protein immunized mice spleen B lymphocyte through a flexible oligonucleotide chain (Linker). Through soluble expression of the single chain antibody, such experiments as enzyme linked immunosorbent assay (ELISA) and immunohistochemistry prove that the single chain antibody has characteristics of broad spectrum recognition, strong specificity and high affinity on three p21ras proteins. An intracellular antibody constructed by the single chain antibody can inhibit proliferations and invasion abilities of the human tumor cells with highly expressed p21ras proteins, and can inhibit growths of transplantation tumors of the human tumor cells with highly expressed p21ras proteins in a mice body. the single chain antibody is proved to be used for constructing micro-molecular antibodies such as the intracellular antibody; therefore, a new way is provided for treatment and research of related tumors.

The invention relates to an artificial endometrium and its preparation and application and particularly relates to an artificial endometrium. The artificial endometrium comprises a biocompatible stent, endometrial stromal cells/epithelial cells and a mixed culture solution. Through a 3D bioprinting technology, the biocompatible stent and the endometrial stromal cells/epithelial cells are processedinto an artificial endometrium with bioactivity. The mixed culture solution comprises a medium and a biohormone. The biocompatible stent is prepared through a 3D printing method. The artificial endometrium can be used as a research tool for pathophysiological mechanisms aiming at artificial endometrial diseases, can be used as a screening model for regulating and affecting factors related to embryo implantation, and can be used as a research tool for preventing or treating directly or indirectly related endometrial lesions caused by any factor.

The invention discloses a production method of a model for retinitis pigmentosa disease on a primate. A certain dosage of sodium iodate is applied to the primate by a way of carotid artery injection. The production method disclosed by the invention is easy and feasible, high in success rate of model production, good in repeatability, and stable in model; the needed drug amount of sodium iodate is less, so that the damage of a large dosage of sodium iodate to the whole body of the animal is avoided, and the animal lives for a long time so as to provide possibility for follow-up tests; the model for any one side or two sides can be produced according to needs; the production of the model for one side cannot cause any damage to a fellow eye so as to ensure the eyesight of the animal for normal life; the self-control study on bilateral eyes can be carried out on one animal so as to provide the credibility of the tests, and reduce the number of required experimental animals. The production method disclosed by the invention provides a good tool for the research on the retinitis pigmentosa, and has important significance for both pathophysiology research and treatment research of the disease.

The invention belongs to the field of biomedical technology and nanotechnology and particularly relates to a preparation method and an application of a novel programmable targeted mixed liposome preparation. The programmable targeted mixed liposome is prepared through two steps as follows: liposome with LA (lactobionic acid) DSPE-PEG2000-LA added is taken as a shell, and a liver targeted PTX (paclitaxel) liposome and a liver-mitochondrion targeted PTX liposome are prepared independently and then mixed. The solubility of an entrapment drug and the bioavailability of the drug can be improved, programmable delivery of the drug towards tumor tissue-cell-organelle is realized, the antitumor treatment effect of the drug is improved, and the liposome can be used for intravenous infusion tumor diagnosis and treatment research.

The invention relates to the technical field of bioengineering. At present, many problems and difficulties exist in treating atrioventricular block through gene transfection and cell transplantation, and the current situation of researchment of biological pacing therapy is considered, so that a method that a tissue engineering conduction bundle is constructed in vitro by utilizing conduction bundle cells and scaffold materials so as to be transplanted to heart for repairing or reconstructing heart conduction path is an ideal solution of atrioventricular block therapy subject. However, no researchment of construction of the tissue engineering conduction bundle is reported at home and abroad. The invention aims to provide the tissue engineering conduction bundle and a construction method thereof. The construction method is characterized in that: heart conduction cells obtained by inducing collagen sponge and marrow mesenchymal stem cells are utilized to construct the tissue engineering conduction bundle. The tissue engineering conduction bundle provided by the invention has the characteristic of electrocardio conduction, can be used for treatment of transplant, and brings hope to treatment of arrhythmia diseases caused by atrioventricular block.